Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a ...

Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...

This article and associated images are based on a poster originally authored by Kamini Magon, Alison Holiday, Iwona Ziomkiewicz, Jonathan Powell, Jon Dunn, David Tickle, David Dexter, Janusz ...

The study also clarifies the functional role of the receptor's conserved sodium-binding pocket, showing that sodium egress strongly promotes activation-related conformational states, including a ...

Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed dioxane derivatives acting as mGluR4 negative allosteric modulators reported to be useful for the treatment of neurodegeneration, metabolic ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

Sage Therapeutics Inc. has synthesized sterol derivatives acting as glutamate receptor ionotropic, NMDA 2A (GRIN2A; GluN2A) negative allosteric modulators reported to be useful for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...